{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:37:30Z","timestamp":1790498250829,"version":"4.1.0"},"reference-count":114,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T00:00:00Z","timestamp":1322006400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The voltage\u2010gated Kv1.3 and the calcium\u2010activated KCa3.1 potassium channel modulate many calcium\u2010dependent cellular processes in immune cells, including T\u2010cell activation and proliferation and have therefore been proposed as novel therapeutic targets for immunomodulation. Kv1.3 is highly expressed in CCR7<jats:sup>\u2212<\/jats:sup> effector memory T cells and is emerging as a target for T\u2010cell\u2010mediated diseases like multiple sclerosis, rheumatoid arthritis, type\u20101 diabetes mellitus, allergic contact dermatitis, and psoriasis. In contrast, KCa3.1 is expressed in CCR7<jats:sup>+<\/jats:sup> naive and central memory T cells, as well as in mast cells, macrophages, dedifferentiated vascular smooth muscle cells, fibroblasts, vascular endothelium, and airway epithelium. Given this expression pattern, KCa3.1 is a potential therapeutic target for conditions ranging from inflammatory bowel disease, multiple sclerosis, arthritis, and asthma to cardiovascular diseases such as atherosclerosis and post\u2010angioplasty restenosis. Results from animal studies have been supportive of the therapeutic potential of both Kv1.3 and KCa3.1 blockers and have also not shown any toxicities associated with pharmacological Kv1.3 and KCa3.1 blockade. To date, two compounds targeting Kv1.3 are in preclinical development, but so far, no Kv1.3 blocker has advanced into clinical trials. KCa3.1 blockers, on the other hand, have been evaluated in clinical trials for sickle cell anemia and exercise\u2010induced asthma, but have so far not shown efficacy. However, the trial results support KCa3.1 as a safe therapeutic target and hopefully will enable clinical trials for other medical conditions that might benefit from KCa3.1 blockade. Drug Dev Res 72:573\u2013584, 2011. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ddr.20467","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T11:35:45Z","timestamp":1322048145000},"page":"573-584","source":"Crossref","is-referenced-by-count":109,"title":["The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression"],"prefix":"10.1002","volume":"72","author":[{"given":"Jenny","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.117"},{"key":"e_1_2_7_3_1","first-page":"281","article-title":"Mammalian osteoclasts express a transient potassium channel with properties of Kv1.3","volume":"2","author":"Arkett SA","year":"1994","journal-title":"Receptors Channels"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780802708011"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.11.1557"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08520.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700717"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm030523s"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.2.936"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241497298"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.008193"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605136103"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409627200"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00362.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(97)00163-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00816.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.2.409"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.03.010"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.042698399"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.8.2.179"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.060319"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/307465a0"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910133107"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.8.4261"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0219-3"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-16-06126.1998"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00844-4"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.9.5746"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi982954w"},{"key":"e_1_2_7_31_1","unstructured":"FlynnB BaellJB HarveyAJ ChaplinJH PaulD MouldJA. 2008a. WO2008040057 Bionomics Limited Australia. Novel benzofuran potassium channel blockers and uses thereof."},{"key":"e_1_2_7_32_1","unstructured":"FlynnB BaellJB HarveyAJ ChaplinJH PaulD MouldJA. 2008b. WO2008040058 Bionomics Limited Australia. Novel chromenone potassium channel blockers and uses thereof."},{"key":"e_1_2_7_33_1","unstructured":"FlynnB BaellJB ChaplinJH GillGS GrobelynDW HarveyAJ MouldJA PaulD.2009. WO2009043117 Bionomics Limited Australia. Novel aryl potassium channel blockers and uses thereof."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)46707-X"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1711"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003941200"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.245"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(98)00427-4"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00132.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-008-0619-x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903458106"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.23.9411"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.102.4.601"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02310.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400733101"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.36.25237"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702480"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn728"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050839v"},{"key":"e_1_2_7_50_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0026-895X(25)10032-1","article-title":"WIN 17317\u20103: novel nonpeptide antagonist of voltage\u2010activated K+ channels in human T lymphocytes","volume":"48","author":"Hill RJ","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00374.2010"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.20.11013"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3593-06.2007"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.280.4.C796"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.0491r.x"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20049"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000086464.04719.DD"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.11.5120"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1999.1569"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21505"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2007.00064.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.52.32723"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00095.2003"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.135244"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1989.sp017712"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1987.sp016750"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.07.015"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/307468a0"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03615.x"},{"key":"e_1_2_7_70_1","first-page":"L334","article-title":"Basolateral K+ channels in airway epithelia. I. Regulation by Ca2+ and block by charybdotoxin","volume":"258","author":"McCann JD","year":"1990","journal-title":"Am J Physiol"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00014-3"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00011a007"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041379"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.85.9.e33"},{"key":"e_1_2_7_76_1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0026-895X(25)09629-4","article-title":"Novel nonpeptide agents potently block the C\u2010type inactivated conformation of Kv1.3 and suppress T cell activation","volume":"50","author":"Nguyen A","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1993.264.4.C1014"},{"key":"e_1_2_7_78_1","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.4049\/jimmunol.148.11.3361","article-title":"Differential regulation of voltage\u2010 and calcium\u2010activated potassium channels in human B lymphocytes","volume":"148","author":"Partiseti M","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002329900601"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.18.13677"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.052704"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.3181\/0705-RM-148"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10171"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.2.1201"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425954"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004009"},{"key":"e_1_2_7_87_1","unstructured":"RobinetteL AbrahamWM BraddingP KrajewskiJ AntonioB SheltonT BannonAW RigdonG KrafteD WagonerK CastleNA.2008.Senicapoc (ICA\u201017043) a potent and selective KCa3.1 K+channel blocker attenuates allergen\u2010induced asthma in sheep. 15th International Conference of the Inflammation Research Association Chantilly VA."},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501770102"},{"key":"e_1_2_7_89_1","first-page":"284","article-title":"Allergic contact dermatitis","volume":"14","author":"Saint\u2010Mezard P","year":"2004","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/44385"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03265.x"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi025722c"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.015669"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2006-0358OC"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.12.8040"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000238377.08219.0c"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.161"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2348"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni0901-762"},{"key":"e_1_2_7_102_1","unstructured":"SullivanJK McGivernJG MirandaLP NguyenHQ WalkerKW HuS GeggCV McDonoughSI.2006. WO2006116156 Amgen. Fusion proteins of toxin peptides with linkers and IgG and their use as therapeutic agents."},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.155796"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30836"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0496-317"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00003.2010"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304388200"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.39.5.469"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.10.11"},{"key":"e_1_2_7_110_1","first-page":"438","article-title":"Targeting effector memory T\u2010cells with Kv1.3 blockers","volume":"10","author":"Wulff H","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.14.8151"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16921"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.776"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707780831186"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2983"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.20467","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.20467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:49:33Z","timestamp":1760345373000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.20467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":114,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1002\/ddr.20467"],"URL":"https:\/\/doi.org\/10.1002\/ddr.20467","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}